Five-year Kymriah data show durable remission, long-term survival in advanced B-cell ALL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure found that carvedilol, a blood vessel relaxing medication, is safe for childhood cancer survivors and may improve important markers of heart injury sustained as a result of chemotherapy exposure.

Login